lpca Laboratories enters into Technology Transfer Agreement with Omexa Formulary

Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market

Celanese and Secarna Pharmaceuticals collaborate for RNA research for antisense therapies

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA

GSK completes acquisition of Aiolos Bio

The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody

UBE announces Phase I clinical trial for SSAO/VAP-1 licensed exclusively to Novo Nordisk

MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,

Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40

GSK to acquire Aiolos Bio for US$ 1 billion upfront payment

Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway

AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan

The deal includes upfront payments, milestone payments and ongoing royalties

AbelZeta Pharma, AstraZeneca to co-develop a novel GPC3 armored CAR-T therapy in China

C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II

Sun Pharmaceutical inks licensing agreement with Aclaris Therapeutics

The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties